Issels Integrative Immuno-Oncology August 9, 2018  

Prostate Biopsy Replaced with MRI Evaluation

Dear Friend,

The collaborative efforts of a multi-institutional study published by JAMA Oncology is changing prostate cancer treatment protocols. Potential prostate cancer patients may no longer need to line up for biopsies. Instead, MRI-based prediction models are offering a new risk assessment option.

Bye-Bye Biopsy

In the study, researchers from the National Cancer Institute, University of Chicago, and University of Alabama at Birmingham (UAB) found evidence that the inclusion of an MRI for prostate cancer patients can be used as a biomarker to decrease unnecessary biopsies. It was also determined that the MRIs helped maintain a high rate of diagnoses for clinically significant prostate cancers.

Hello MRI

Based on the data collected the research points to MRI-based models as further offering the benefit of lower false-positive rates than the baseline model. This means 18% fewer men would be subject to unnecessary biopsies subsequent to false-positive diagnosis.

Next Destination: Improved Cancer Treatment

Co-Author of the study, UAB Department of Urology Assistant Professor and UAB Comprehensive Cancer Center Associate Scientist Soroush Rais-Bahrami, M.D., points to the data's far-reaching implications. The imaging biomarker is expected to optimize patient selection, as well as allow for the more accurate determination of risk factors and stratification.

What's more, it will provide physicians with the opportunity to potentially reduce prostate cancer morbidity by enabling a more timely and accurate diagnosis, and thus a faster, more individualized treatment response for prostate cancer treatment patients.

Looking for an alternative approach to cancer treatment? Issels® has you covered. Contact us to learn more about our individualized, non-toxic immunotherapy options. Bring your body back to health with the help of Issels® today.

Email   Facebook   Twitter   Google+

Prostate Biopsies Replaced with MRI Evaluation

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »


Prostate Screening Using PSA Tests Appears To Miss Many Aggressive Cancers

In response to a debate about whether or not the country's National Health Service should institute a national prostate cancer screening program, Cancer Research UK funded a study to evaluate the effectiveness of PSA testing. Subjects included 400,000 men between the ages of 50 and 69.

Results showed that death rates among men in the group were identical, regardless of whether or not they received a PSA test. The screening failed to detect several cases of aggressive prostate cancer while causing unnecessary stress by flagging benign tumors.

Get the Full Story!

New Blood Test Identifies Which Prostate Cancer Patients Will Respond Favorably To Specific Medications

No two cases of cancer are identical, which makes it a challenge to determine what course of cancer treatment will be most effective. Scientists are excited about a new three-in-one blood test that may open the door for precision treatment of advanced prostate cancer.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!
Interested?

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:


Google +

Contact Info:

Phone: 888-447-7357

Email: info@issels.com



Treatments | Testimonials | Contact Us